Charles Haworth is Director of the Cambridge Centre for Lung Infection (incorporating The Adult Cystic Fibrosis Centre, The Lung Defence Clinic and The Respiratory Immunology Clinic) at Royal Papworth Hospital. He is also an Honorary Consultant at Addenbrooke’s Hospital in Cambridge.
The Adult Cystic Fibrosis Centre oversees the care of >330 adults with CF. The Lung Defence Clinic oversees the care of >2000 patients with bronchiectasis associated with primary and secondary immunodeficiencies, non-tuberculous mycobacterial (NTM) lung disease, Aspergillus related lung disease, rheumatoid arthritis, serious childhood infection, chronic aspiration and primary ciliary dyskinesia.
Both the Adult Cystic Fibrosis Centre and Lung Defence Clinic have European Reference Network (ERN) designation.
Charles Haworth trained at the Manchester Adult Cystic Fibrosis Centre, Hammersmith Hospital and the Royal Brompton Hospital before moving to Cambridge in 2003.
Dr Haworth is the senior author of the US Cystic Fibrosis Foundation & European Cystic Fibrosis Society NTM guidelines published in 2016 and first author of the British Thoracic Society NTM guidelines published in 2017. He also co-authored the European Respiratory Society Bronchiectasis guidelines published in September 2017 and is a member of the British Thoracic Society Bronchiectasis guidelines committee.
Dr Haworth is an Honorary Visiting Senior Fellow in the Department of Medicine at the University of Cambridge; he is a member of two European Union Framework Programme 7 funded research consortia (iABC and CFMATTERS); he is co-chief investigator of three current international multicentre novel therapy clinical trials in people with bronchiectasis; he is the Papworth site Principal Investigator for the European Cystic Fibrosis Society Clinical Trials network; he is a member of the US Cystic Fibrosis Foundation Data Safety Monitoring Board; he is a Steering Committee and Scientific Committee member of the European Bronchiectasis Registry (EMBARC); he is a member of the Cystic Fibrosis Trust Strategic Implementation Board; and a member of the European Cystic Fibrosis Society Scientific Committee.
Cystic Fibrosis
Bronchiectasis
Asthma / COPD with infection
Complex lung infection (including Pseudomonas aeruginosa, Non Tuberculous Mycobacteria and Aspergillus)
Primary Ciliary Dyskinesia
Immunodeficiency
Epidemiology and treatment of lung infection in patients with CF and non-CF bronchiectasis.
1993 M.B.Ch.B. Manchester University
1996 M.R.C.P. London
2003 M.D. Manchester University
2003 CCST in Respiratory Medicine
2003 Respiratory Medicine Specialist Register
2007 F.R.C.P. London
European Cystic Fibrosis Society
British Thoracic Society
European Respiratory Society
American Thoracic Society
Fellow, Royal College of Physicians of London
Visiting Senior Fellow, Department of Medicine, University of Cambridge
Peer reviewed publications:
Haworth CS, Selby PL, Webb AK, Mawer EB, Adams JE, Freemont AJ. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998;352:1753-1754
Haworth CS, Niven R, Moorcroft AJ, Phillips A, Dodd ME, Webb AK. Acute anaphylaxis following midline catheterisiation in a patient with cystic fibrosis. Thorax 1999;54:747.
Haworth CS, Freemont AJ, Webb AK, Dodd ME, Selby PL, Mawer EB, Adams JE. Hip fracture and bone histomorphometry in a young adult with cystic fibrosis. Eur Resp J 1999;14:478-479
Haworth CS, Selby PL, Webb AK, Dodd ME, Musson H, Niven R M, Economou G, Horrocks AW, Freemont AJ, Mawer EB, Adams JE. Low bone mineral density in cystic fibrosis adults. Thorax 1999;54:961-967 Editorial: Conway SP. Bone mineral density in adults with cystic fibrosis. Thorax 1999;54:957
Haworth CS, Dodd ME, Atkins M, Woodcock AA, Webb AK. Pneumothorax in cystic fibrosis adults dependent on nasal intermittent positive pressure ventilation (NIPPV): a management dilemma. Thorax 2000;55:620-623.
Haworth CS, Webb AK, Egan JJ, Selby PL, Hasleton PS, Bishop PW, Freemont AJ. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000;118:434-439
Dodd ME, Kellet F, Davis A, Simpson JCG, Webb AK, Haworth CS, Niven RML. An audit of oxygen prescribing by doctors: a specific oxygen prescription chart improves clinical practice. BMJ 2000;321:864-865
Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AW, Webb AK. The effect of intravenous pamidronate in adults with cystic fibrosis. Thorax 2001;56:314-316
Haworth CS, Selby PL, Horrocks AW, Mawer EB, Adams JE, Webb AK. A prospective study of change in bone mineral density over one year in 114 adults with cystic fibrosis. Thorax 2002;57:719-723
Haworth CS, Selby PL, Webb AK, Martin L, Elborn S, Sharples L, Adams JE. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004;59:613-617
Haworth CS, Jones AM, Selby PL, Webb AK, Adams JE. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. J Cyst Fibros 2004;3:233-236
Chapman E, Landy A, Lyon A, Haworth CS, Bilton D. End of life care for adult cystic fibrosis patients: Facilitating a good enough death. J Cyst Fibros 2005;4(4):249-257
Aris RM on behalf of the Cystic Fibrosis Foundation Consensus Bone Health Group. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90:1888-1896
Shead EL, Haworth CS, Gunn E, Bilton D, Scott MA, Compston JE. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Resp Crit Care Med 2006;174(3):306-311
Fowler SJ, French J, Screaton NJ, Foweraker J, Condliffe A, Haworth CS, Exley AR, Bilton D. Non-tuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Resp J 2006;28(6):1204-1210
Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax. 2007;62(7):650-651
Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis related diabetes. Diabetic Medicine 2007;24:1143-1148
Nash KL, Allison ME, McKeon D, Lomas DA, Haworth CS, Bilton D, Alexander GJ. A single centre experience of liver disease in adults with cystic fibrosis 1995-2005. J Cyst Fibros 2008;7(3):252-257
Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008;31(9):1789-1794.
Barker HC, Haworth CS, Williams D, Roberts P, Bilton D. Clostridium difficile pancolitis in adults with cystic fibrosis. J Cyst Fibros. 2008;7(5):444-447
Gilham MI, Sundaram S, Laughton CR, Haworth CS, Bilton D, Foweraker JE. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J Antimicrob Chemother 2009;63:728-732
McKeon DJ, Cadwalladwe KA, Idreis S, Cowburn AS, Pasteur MC, Barker HC, Haworth CS, Bilton D, Chilvers ER, Condliffe AM. Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation. Eur Respir J 2010;35:1264-1272
Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as determinants of mortality in cystic fibrosis. Diabetes care 2010;33:311-316
Shead EF, Haworth CS, Barker HC, Bilton D, Compston JE. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros 2010;9:93-98
Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris R, Morton A, Hardin D, Elkin SL, Compston JE, Conway P, Castanet M, Wolfe S, Haworth CS. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011;Suppl 2:S16-23
Adler AI, Shine B, Haworth CS, Leelarathna L, Bilton D. Hyperglycaemia and death in cystic fibrosis related diabetes. Diabetes Care 2011;34:1577-1588
Renna M, Schaffner C, Brown K, Shang S, Henao Tamayo M, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton S, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA. Azithromycin blocks autophagy and may predispose to mycobacterial infection. J Clin Invest. 2011 Sep 1;121(9):3554-3563
Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson ME, Conway SP, Etherington C, Elborn JS, Rendall J, Wheaton E, Kadri E, Elliott J, Barker HC, Bearcroft PWP, Hlaing T, Compston JE. Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. J Cyst Fibros. 2011;10:470-476
Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, Peacock SJ, Parkhill J, Floto RA. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013;381:1551-1560
Haworth CS, Foweraker J, Wilkinson PW, Kenyon P, Bilton D. Inhaled Colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Resp Crit Care Med 2014;189:975-982 (with accompanying editorial)
Hurst JR, Elborn JS, De Soysa A on behalf of the Bronch-UK investigators, COPD-Bronchiectasis overlap syndrome. Eur Resp J 2015
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L,Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace R, Winthrop KL, Marshall BC, Haworth CS. Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Recommendations for the management of nontuberculous in individuals with cystic fibrosis: executive summary Thorax 2016;71:88-90
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L,Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace R, Winthrop KL, Marshall BC, Haworth CS. Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Recommendations for the management of nontuberculous in individuals with cystic fibrosis. Thorax 2016;71 Suppl 1:i1-i22
Viviani L, Harrison MJ, Zolin A, Haworth CS, Floto RA. Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis. J Cyst Fibros 2016;15:619-623
Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Emily Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler ICJW, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O’Brien C, O’Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA. Emergence and spread of a human- transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016;354:751-757
Hilliam Y, Moore M, Lamont I, Bilton D, Haworth CS, Foweraker J, Walshaw M, Williams D, Fothergill J, De Soyza A, Winstanley C. Pseudomonas aeruginosa adaptation and diversity in the non-cystic fibrosis bronchiectasis lung. Eur Respir J 2017;49:1602108 [https://doi. org/10.1183/13993003.02108-2016].
Plant B, Eustace J, Jone AM, Haworth CS, Bilton D, Ketchell I, Gunaratnam C, Peckham D, A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. J Cyst Fibros 2017 Apr 6.pii: S1569-1993(17)30031-0. doi: 10.1016/j.jcf.2017.02.006
Van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffiths DE. Poor adherence to management guidelines in nontuberculous pulmonary mycobacterial diseases. Eur Respir J 2017 Feb 15;49(2). pii: 1601855. doi: 10.1183/13993003.01855-2016
*Hill A, *Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers J, De Soyza A, Dimakou K, Elborn J, Feldman C, Flume P, Goeminne P, Loebinger M, Menéndez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen F, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O’Donnell A, Aksamit T. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017 *Joint first author
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017 Sep 9;50(3). pii: 1700629. doi: 10.1183/13993003.00629-2017.
Haworth CS, Floto RA. Introducing the new British Thoracic Society Guidelines for the Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD). Thorax. 2017 Nov;72(11):969-970
Haworth CS, Banks J, Capstick T, Fisher A, Gorsuch T, Laurenson IF, Leitch A, Loebinger M, Milburn H, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. British Thoracic Society Guidelines for the Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD). Thorax. 2017 Nov;72(Suppl 2):1-64
Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S Goeminne PC, Winstanley C, De Soyza A. Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. Eur Respir J. 2018 Jan 11;51(1). pii: 1701937. doi: 10.1183/13993003.01937-2017
Haworth CS, Banks J, Capstick T, Fisher A, Gorsuch T, Laurenson IF, Leitch A, Loebinger M, Milburn H, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. British Thoracic Society Guidelines for the Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD). BMJ Open Respir Res. 2017 Oct 19;4(1):e000242. doi: 10.1136/bmjresp-2017-000242.
Bedi P, Chalmers JD, Goeminne PC, Mai C, Saravanamuthu P, Velu PP, Cartlidge MK, Loebinger MR, Jacob J, Kamal F, Schembri N, Aliberti S, Hill U, Harrison M, Johnson C, Screaton N, Haworth CS, Polverino E, Rosales E, Torres A, Benegas MN, Rossi AG, Patel D, Hill AT. The BRICS (Bronchiectasis Radiologically Indexed CT Score): A multicenter study score for use in idiopathic and postinfective bronchiectasis. Bedi P, Chalmers JD, Goeminne PC, Mai C, Saravanamuthu P, Velu PP, Cartlidge MK, Loebinger MR, Jacob J, Kamal F, Schembri N, Aliberti S, Hill U, Harrison M, Johnson C, Screaton N, Haworth CS, Polverino E, Rosales E, Torres A, Benegas MN, Rossi AG, Patel D, Hill AT. Chest. 2018 May;153(5):1177-1186. doi: 10.1016/j.chest.2017.11.033. Epub 2017 Dec 13.
Book chapters:
Haworth CS, Webb AK. Cystic Fibrosis. In: Grassi C, ed. Pulmonary Diseases. London: McGraw-Hill, 1999:115-125
Haworth CS, Elkin SL. Bone Mineralisation in Cystic Fibrosis. In: Webb AK and Ratjen F, Eds. Cystic Fibrosis. Eur Resp J Monograph April 2006
Elkin SL, Haworth CS. Cystic Fibrosis Related Low Bone Mineral Density. In: Hodson, Geddes & Bush A, Eds. Cystic Fibrosis, Third Edition, 2007.
Haworth CS. Metabolic and musculoskeletal effects of cystic fibrosis. In: Innes A, Cunningham S, Horsley A, Eds. Cystic Fibrosis, Oxford Respiratory Medicine, 2010.
Haworth CS. Antibiotic treatment strategies in adults with bronchiectasis. In Floto RA and Haworth CS. Eds. Bronchiectasis. Eur Resp J Monograph, Number 52, June 2011
Hill UG, Haworth CS. Metabolic and musculoskeletal effects of cystic fibrosis. In: Innes A, Cunningham S, Horsley A, Eds. Cystic Fibrosis, Oxford Respiratory Medicine, Second edition, 2015.
Shteinberg M, Johnson C, Haworth CS. Antibiotic treatment in bronchiectasis. In press.
Contact details:
SwitchBoard: 01223 638000
Secretary
Cate Bromley
Telephone: 01223 639789
Email: catherine.bromley1@nhs.net